View Older Stories View More Recent Stories

Oct 3, 2023 04:30PM Athersys Licenses its Animal Health Assets to Ardent Animal Health
Oct 2, 2023 05:06PM Athersys (ATHX) Director Jane Wasman Appointed Board Chair
Oct 2, 2023 05:04PM Athersys Director Jane Wasman Appointed Board Chair
Sep 6, 2023 02:45PM Grant Awarded to Newcastle University to Research Athersys’ MultiStem® in Machine Perfusion Prior to Kidney Transplantation
Aug 18, 2023 05:42AM Athersys (ATHX) Prices 10.94M Share Offering at $0.32/sh
Aug 17, 2023 09:30PM Athersys, Inc. Announces Pricing of $3.5 Million Public Offering
Aug 16, 2023 05:01PM Athersys (ATHX) Reports Q2, Provides Updates
Aug 16, 2023 05:01PM Athersys Reports Second Quarter 2023 Financial Results and Business Highlights
Aug 11, 2023 08:01AM Athersys (ATHX) Appoints Neema Mayhugh to its Board
Aug 11, 2023 08:00AM Athersys Appoints Neema Mayhugh, PhD to its Board of Directors
Jul 31, 2023 01:38PM Athersys to Host Business Update Conference Call on August 9th
Jun 1, 2023 04:40PM Patient Enrollment Begins in Third and Final Cohort of the Phase 2 MATRICS-1 Clinical Study Evaluating Athersys’ MultiStem® Following Hemorrhagic Trauma
May 23, 2023 08:30AM Athersys Restructures Debt with Supplier
May 18, 2023 09:58AM Athersys Reports First Quarter 2023 Financial Results and Business Highlights
May 8, 2023 09:49AM Athersys to Participate in Three Upcoming Conferences
May 1, 2023 08:30AM Athersys to Participate in The Cellular Therapies and Transfusion Medicine in Trauma and Critical Care Conference
Apr 21, 2023 02:23PM Athersys to Participate in The American Society for Neural Therapy and Repair Annual Conference
Apr 19, 2023 04:01PM Athersys, Inc. Announces Closing of $3.7 Million Registered Direct Offering and Concurrent Private Placement
Apr 18, 2023 08:06AM Athersys (ATHX) Announces 3.7M Share Offering at $1/sh
Apr 18, 2023 08:00AM Athersys, Inc. Announces $3.7 Million Registered Direct Offering and Concurrent Private Placement
Apr 10, 2023 03:29PM Athersys to Host Business Update Conference Call on April 20th
Mar 31, 2023 06:26PM Athersys Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
Mar 22, 2023 08:30AM Athersys (ATHX) Announces Successful Type B Meeting with the FDA
Mar 22, 2023 08:30AM Athersys Announces Successful Type B Meeting with the FDA
Feb 28, 2023 08:15AM Athersys Expands IP Protection with First New Patent for SIFU® Technology
Feb 14, 2023 08:34AM Athersys (ATHX) Granted Clinical Type B Meeting with FDA for MASTERS-2 Clinical Trial Protocol Discussion
Feb 14, 2023 08:33AM Athersys Granted Clinical Type B Meeting with FDA for MASTERS-2 Clinical Trial Protocol Discussion
Feb 2, 2023 08:30AM Athersys to Host Business Update Conference Call on February 14th
Jan 30, 2023 11:20AM Athersys to Participate in International Stroke Conference and BioProcess International
Jan 11, 2023 12:11PM Athersys to Participate in Advanced Therapies Week and Allogeneic Cell Therapies Summit Europe in January
Jan 9, 2023 08:34AM Athersys (ATHX) Provides MultiStem Clinical Update
Jan 9, 2023 08:30AM Athersys Provides MultiStem Clinical Update
Jan 5, 2023 04:33PM Athersys (ATHX) Appoints Joseph Nolan to Its Board
Jan 5, 2023 04:33PM Athersys Appoints Joseph Nolan to Its Board of Directors
Nov 15, 2022 08:00AM Athersys Reports Third Quarter 2022 Financial Results and Provides Business Update
Nov 11, 2022 08:30AM Athersys to Present at Challenges and Opportunities for Mesenchymal Stem Cells Digital Conference and Participate in A.G.P.’s Biotech Conference
Nov 10, 2022 03:12PM Athersys, Inc. Announces Closing of $5.5 Million Confidentially Marketed Public Offering
Nov 10, 2022 08:55AM Athersys Reschedules Third Quarter Conference Call to November 15
Oct 25, 2022 08:30AM Athersys to Host Third Quarter Financial Results Call
Oct 4, 2022 09:25AM Athersys to Present at 2022 Cell & Gene Meeting on the Mesa Conference and Attend 14th World Stroke Congress in October
Sep 30, 2022 12:33PM Athersys to Host Business Update Conference Call on October 6th
Sep 23, 2022 09:20AM Athersys (ATHX) Amends Securities Purchase Agreement in Connection with Recent Registered Direct Offering
Sep 23, 2022 09:19AM Athersys Amends Securities Purchase Agreement in Connection with Recent Registered Direct Offering
Aug 25, 2022 04:32PM Athersys (ATHX) Announces 1:25 Reverse Stock Split
Aug 25, 2022 04:30PM Athersys Announces 1-for-25 Reverse Stock Split
Aug 17, 2022 04:30PM Athersys, Inc. Announces Closing of $12 Million Registered Direct Offering
Aug 15, 2022 08:31AM Athersys (ATHX) Prices 48M Share Direct Offering at $0.25/sh
Aug 15, 2022 08:30AM Athersys, Inc. Announces $12 Million Registered Direct Offering
Aug 11, 2022 04:17PM Athersys Reports Second Quarter 2022 Financial Results and Provides Business Update
Aug 8, 2022 09:40AM Athersys (ATHX) Announces Favorable Preclinical Results for MultiStem Treatment in Defense Department Radiation Countermeasure Study
View More Recent Stories View Older Stories